Doha-based Weill Cornell Medicine-Qatar (WCM-Q) has said that it has signed a research agreement with US-based biotechnology company, Moderna, it was reported on Monday.
The two firms are to work together to develop a new drug for controlling cholesterol. The firms are hoping that the new drug would improve treatments for type 2 diabetes and cardiovascular disease.
The agreement would see Moderna sponsor a study by WCM-Q researcher, Dr Hani Najafi.
Since its launch in 2010, Moderna has developed a technology platform for developing mRNA-based therapies.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes